Meet Proteona at the AVCO Annual Conference 2019 in Vienna, Austria
Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology
Dr Andreas Schmidt, the CEO of Proteona Pte. Ltd., will be presenting at the AVCO Annual Conference 2019, taking place on the 3rd of October in Vienna, Austria.
Dr Schmidt will speak in the panel “Investing in Healthcare Opportunities in Europe” at 17:10pm. The annual conference is Austria’s leading event for investors and entrepreneurs.
For media queries, please contact:
Dr Andreas Schmidt
Proteona Pte. Ltd. is a biomedical company in Singapore, Germany, and the US that is pioneering the use of single cell proteogenomics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona provides a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR). Proteona is leading an international alliance to develop neutralizing antibodies against coronaviruses including SARS-CoV-2. In addition, Proteona supports partners developing COVID-19 therapies and vaccines by providing single cell immune profiling services.